Pfizer Upgraded at Barclays
Shares of Pfizer were slightly higher on Tuesday as Barclays upgraded its rating to Overweight from Equal Weight
Shares of Pfizer (PFE) - Get Report were slightly higher on Tuesday as Barclays upgraded its rating to Overweight from Equal Weight. The firm also increased its price target by $1 to $38 per share. Analysts at Barclays said the drug manufacturer should be able to use foreign cash for productive M&A activities and to return capital to shareholders. The analysts also believe that the oncology business will drive growth.
Employees of TheStreet are restricted from trading individual securities.
